Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy
Go back to Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy| Amgen Inc (NASDAQ: AMGN) | Delayed: 344.72 +7.12 (2.11%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $337.60 | 52 Week High | $176.85 | |||
| Open | $337.65 | 52 Week Low | $133.64 | |||
| Day High | $345.11 | P/E | 51.92 | |||
| Day Low | $337.60 | EPS | $6.64 | |||
| Volume | 2,520,731 | |||||
| (NASDAQ: ZLAB) | Delayed: 18.48 +0.30 (1.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.18 | 52 Week High | $ | |||
| Open | $17.81 | 52 Week Low | $ | |||
| Day High | $18.60 | P/E | N/A | |||
| Day Low | $17.75 | EPS | $ | |||
| Volume | 913,241 | |||||
